Clinical Trials Register

Trials with a EudraCT protocol (23)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

23 result(s) found for: Lymphoproliferative disorders. Displaying page 1 of 2.

EudraCT Number: 2015-005454-35

Sponsor Protocol Number: RG_15-235

Start Date*: 2016-09-23

Sponsor Name:University of Birmingham

Full Title: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Medical condition: Post-transplant lymphoproliferative disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10051358	Post transplant lymphoproliferative disorder	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2013-004479-11

Sponsor Protocol Number: DPTLDSG-IIT-PTLD-2

Start Date*: 2014-09-19

Sponsor Name:DIAKO Ev. Diakonie-Krankenhaus Bremen gGmbH

Full Title: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined W...

Medical condition: Previously untreated CD20-positive lymphoproliferative disorder (PTLD) following solid organ transplantation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10051358	Post transplant lymphoproliferative disorder	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2011-004657-11

Sponsor Protocol Number: VI-Plt-01

Start Date*: 2012-03-30

Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA

Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)

Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10005329 - Blood and lymphatic system disorders	10050245	Autoimmune thrombocytopenia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-000492-21	Sponsor Protocol Number: 7678	Start Date*: 2021-06-11
Sponsor Name:Les Hôpitaux Universitaires de Strasbourg
Full Title: Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in adult EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant ...
Medical condition: Kidney transplantation Epstein Barr virus
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-003982-17

Sponsor Protocol Number: SGN35-015

Start Date*: 2020-10-21

Sponsor Name:SEATTLE GENETICS, INC.

Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...

Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10020328	Hodgkin's lymphoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10034623	Peripheral T-cell lymphoma unspecified	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10034624	Peripheral T-cell lymphoma unspecified NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073478	Anaplastic large-cell lymphoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001412	Adult T-cell leukemia-lymphoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065855	Extranodal NK/T-cell lymphoma, nasal type	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073481	Enteropathy-associated T-cell lymphoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10022703	Intestinal T-cell lymphoma	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061232	Lymphoproliferative disorder	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066957	Hepatosplenic T-cell lymphoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002449	Angioimmunoblastic T-cell lymphoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042971	T-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2019-003983-28

Sponsor Protocol Number: SGN35-028

Start Date*: 2020-11-27

Sponsor Name:SEAGEN INC.

Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma...

Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073478	Anaplastic large-cell lymphoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10020328	Hodgkin's lymphoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10034623	Peripheral T-cell lymphoma unspecified	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10034624	Peripheral T-cell lymphoma unspecified NOS	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001412	Adult T-cell leukemia-lymphoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065855	Extranodal NK/T-cell lymphoma, nasal type	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073481	Enteropathy-associated T-cell lymphoma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10022703	Intestinal T-cell lymphoma	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061232	Lymphoproliferative disorder	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066957	Hepatosplenic T-cell lymphoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10002449	Angioimmunoblastic T-cell lymphoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042971	T-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2005-004105-28

Sponsor Protocol Number: 291-420

Start Date*: 2006-06-20

Sponsor Name:PDL BioPharma, Inc.

Full Title: An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.

Medical condition: Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.0		10045265		LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) NL (Ongoing) GR (Prematurely Ended) FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2006-002971-42

Sponsor Protocol Number: PEG-HSR

Start Date*: 2006-06-19

Sponsor Name:OSPEDALE S. RAFFAELE

Full Title: Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.

Medical condition: patients affected by linphoproliferative pathologies

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10005329	Blood and lymphatic system disorders	SOC

Population Age: Adults

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2006-006373-25

Sponsor Protocol Number: A3921029

Start Date*: 2007-03-23

Sponsor Name:Pfizer, S.A.

Full Title: ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBS...

Medical condition: CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease mo...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10039073	Rheumatoid arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) AT (Completed) SE (Completed) SK (Completed) CZ (Completed) GR (Completed) DE (Completed) FI (Completed) BG (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2009-011817-26	Sponsor Protocol Number: BHS-UCB2009	Start Date*: 2010-10-21
Sponsor Name:UZ Brussel VUB
Full Title: A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning ...
Medical condition: Adult patients with hematological malignancies
Disease:
Population Age: Adolescents, Under 18, Adults		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: (No results available)

EudraCT Number: 2019-000720-17

Sponsor Protocol Number: MOM-M281-006

Start Date*: 2020-01-14

Sponsor Name:Janssen-Cilag International NV

Full Title: Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension

Medical condition: Adults with Warm Autoimmune Hemolytic Anemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004851	10002285	Anemia hemolytic autoimmune (NOS)	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Temporarily Halted) HU (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-005152-34

Sponsor Protocol Number: HOWLONG

Start Date*: 2012-03-26

Sponsor Name:José Miguel Cisneros Herreros

Full Title: Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia

Medical condition: In-hospital adult patients diagnosed with acute leukemia, lymphoproliferative syndrome, multiple myeloma, myelodysplastic syndrome, aplastic anemia or who have received autologous or allogeneic tra...

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10005329 - Blood and lymphatic system disorders	10016288	Febrile neutropenia	PT
	14.0	10042613 - Surgical and medical procedures	10066156	Empiric treatment	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: (No results available)

EudraCT Number: 2016-003286-26

Sponsor Protocol Number: PCYC-1140-IM

Start Date*: 2017-04-18

Sponsor Name:Pharmacyclics LLC

Full Title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Dis...

Medical condition: Chronic Graft Versus Host Disease (cGVHD)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10021428 - Immune system disorders	10066261	Chronic graft versus host disease	PT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: HU (Completed) DE (Completed) ES (Completed) AT (Completed) HR (Completed) IT (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2009-015767-14

Sponsor Protocol Number: FER-FID-CHEMO

Start Date*: Information not available in EudraCT

Sponsor Name:Vifor (International) AG

Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies...

Medical condition: Anaemic subjects with lymphoid malignancies and functional iron deficiency receiving chemotherapy

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025631	Malignant lymphoid neoplasm NOS	LLT
	14.0	10005329 - Blood and lymphatic system disorders	10002034	Anaemia	PT
	14.0	10027433 - Metabolism and nutrition disorders	10022970	Iron deficiency	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) SE (Prematurely Ended) AT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2008-000454-12

Sponsor Protocol Number: P05315

Start Date*: 2009-03-03

Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation

Full Title: A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.

Medical condition: Moderate to severe plaque Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	11.0		10037153		LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) DE (Completed) ES (Prematurely Ended) DK (Completed) HU (Prematurely Ended) FR (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2008-000252-28

Sponsor Protocol Number: SHCVOLT1

Start Date*: 2009-03-13

Sponsor Name:Cambridge University Hospitals NHS Foundation Trust

Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...

Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10052779	Transplant rejections	HLT
	9.1		10024970	Respiratory tract infections	HLGT
	9.1		10046577	Urinary tract infections	HLT
	9.1		10001032	Acute pyelonephritis	LLT
	9.1		10040072	Septicaemia	LLT
	9.1		10019972	Herpes viral infections	HLT
	9.1		10028440	Mycobacterial infectious disorders	HLGT
	9.1		10015107	Epstein-Barr viral infections	HLT
	9.1		10011831	Cytomegalovirus infection	LLT
	9.1		10019974	Herpes zoster	LLT
	9.1		10058872	Fungal sepsis	LLT
	9.1		10040808	Skin cancer	PT
	9.1		10051358	Post transplant lymphoproliferative disorder	LLT
	9.1		10043555	Thrombocytopenias	HLT
	9.1		10037561	Purpura thrombocytopenic	LLT
	9.1		10002034	Anaemia	PT
	9.1		10018932	Haemolytic uraemic syndrome	PT
	9.1		10024384	Leukopenia	PT
	9.1		10029355	Neutropenias	HLT
	9.1		10033661	Pancytopenia	PT
	9.1		10013505	Disturbance of liver function tests	LLT
	9.1		10002218	Anaphylaxis	LLT
	9.1		10002425	Angioedemas	HLT
	9.1		10015665	Exfoliative dermatitis	LLT
	9.1		10020764	Hypersensitivity vasculitis	LLT
	9.1		10021015	Hypokalaemia	PT
	9.1		10021058	Hypophosphataemia	PT
	9.1		10020603	Hypercholesterolaemia	PT
	9.1		10020635	Hyperglycaemia	PT
	9.1		10020869	Hypertriglyceridaemia	PT
	9.1		10043071	Tachycardia	PT
	9.1		10034474	Pericardial effusion	PT
	9.1		10048642	Lymphocele	PT
	9.1		10051055	Deep vein thrombosis	PT
	9.1		10037377	Pulmonary embolism	PT
	9.1		10025282	Lymphoedema	PT
	9.1		10035742	Pneumonitis	PT
	9.1		10035598	Pleural effusion	PT
	9.1		10015090	Epistaxis	PT
	9.1		10037394	Pulmonary haemorrhage	PT
	9.1		10000081	Abdominal pain	PT
	9.1		10012735	Diarrhoea	PT
	9.1		10042128	Stomatitis	PT
	9.1		10033645	Pancreatitis	PT
	9.1		10000496	Acne	PT
	9.1		10037844	Rash	PT
	9.1		10003239	Arthralgia	PT
	9.1		10031264	Osteonecrosis	PT
	9.1		10037032	Proteinuria	PT
	9.1		10029164	Nephrotic syndrome	PT
	9.1		10030124	Oedema peripheral	PT
	9.1		10021519	Impaired healing	PT
	9.1		10030095	Oedema	PT
	9.1		10037660	Pyrexia	PT
	9.1		10005630	Blood lactate dehydrogenase increased	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2017-003538-10

Sponsor Protocol Number: BIVV009-03

Start Date*: 2017-11-15

Sponsor Name:Bioverativ USA Inc.

Full Title: A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION

Medical condition: Primary Cold Agglutinin Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10073785	Autoimmune haemolytic anaemia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) ES (Completed) BE (Completed) NL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2021-003160-27	Sponsor Protocol Number: Sobi.PEGCET-101	Start Date*: 2022-05-31
Sponsor Name:Swedish Orphan Biovitrum AB
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
Medical condition: Patients with Cold Agglutinin Disease (CAD)
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Completed) IT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2007-005009-24

Sponsor Protocol Number: INO-0107

Start Date*: 2008-05-15

Sponsor Name:EUSA Pharma

Full Title: An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease...

Medical condition: Steroid refractory acute Graft versus Host Disease (aGvHD) after Allogeneic Haematopoietic Stem Cell Transplantation in adult patients

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10018651	Graft versus host disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2016-002004-10

Sponsor Protocol Number: 15-007

Start Date*: 2016-10-13

Sponsor Name:Jazz Pharmaceuticals, Inc.

Full Title: A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Un...

Medical condition: Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplant

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10019805 - Hepatobiliary disorders	10047207	Veno-occlusive liver damage	LLT
	19.0	10019805 - Hepatobiliary disorders	10047217	Venoocclusive syndrome of the liver	LLT
	19.0	10019805 - Hepatobiliary disorders	10047216	Venoocclusive liver disease	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) GB (Completed) BE (Completed) DE (Prematurely Ended) FR (Completed) IT (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Lymphoproliferative disorders